Pharmacokinetics, safety, tolerability, and immunogenicity of FKB238, a new biosimilar of bevacizumab, in healthy participants
Author:
Boyce Malcolm,Wilkes Denisa,Kaito Hidekuni,Takanuma Masayuki,Arai Yasumasa
Publisher
Dustri-Verlgag Dr. Karl Feistle
Subject
Pharmacology (medical),Pharmacology
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Emerging role of biosimilars: Focus on Bevacizumab and hepatocellular carcinoma;Computational Methods in Drug Discovery and Repurposing for Cancer Therapy;2023